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Objectives The aim of this study was to investigate the relationship between platelet reactivity (PR) after a loading dose
(LD) of prasugrel and thrombotic events.
Background Post-treatment PR has been shown to be strongly associated with the occurrence of major adverse cardiac
events (MACE) after percutaneous coronary intervention (PCI) in the clopidogrel era. Prasugrel is a new
P2Y12–adenosine diphosphate receptor with a higher potency on PR.
Methods A prospective multicenter study included patients who underwent successful PCI for acute coronary syndromes
and received prasugrel therapy. Vasodilator-stimulated phosphoprotein (VASP) index was measured after the
prasugrel LD. High on-treatment PR was defined as a VASP index 50%. MACE included cardiovascular death,
myocardial infarction, and definite stent thrombosis at 1 month.
Results Three hundred one patients were enrolled. The mean VASP index after 60 mg of prasugrel was 34.3  23.1%.
High on-treatment PR was observed in 76 patients (25.2%). Patients experiencing thrombotic events after PCI
had significantly higher VASP indexes compared with those free of events (64.4  14.4% vs. 33.4  22.7%;
range: 51% to 64% and 5% to 47.6%, respectively; p  0.001). Kaplan-Meier analysis comparing good respond-
ers and patients with high on-treatment PR demonstrated a significantly higher rate of MACE in patients with
suboptimal PR inhibition (log-rank p  0.001). Receiver-operating characteristic curve analysis found a cutoff
value of 53.5% of the VASP index to predict thrombotic events at 1 month (r  0.86, p  0.001). Patients with
minor or major Thrombolysis In Myocardial Infarction unrelated to coronary artery bypass grafting bleeding and
those without had similar VASP indexes (30  17.8% vs. 34.3  23%, p  0.70).
Conclusions Despite the use of prasugrel, a significant number of patients undergoing PCI in the setting of acute coronary
syndromes do not achieve optimal PR inhibition. Such patients have a higher risk for MACE after PCI. (J Am
Coll Cardiol 2011;58:467–73) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.017The addition of clopidogrel to aspirin in patients undergo-
ing percutaneous coronary intervention (PCI) for acute
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Prasugrel and Thrombotic Events After PCI July 26, 2011:467–73has 3 main limitations: a slow
onset of action, mild potency,
and large interindividual variabil-
ity in response (2,3). Of impor-
tance, several studies have high-
lighted a link between high on-
treatment platelet reactivity
(HTPR), or suboptimal platelet
reactivity (PR) inhibition, as
measured by platelet assays after
a clopidogrel loading dose (LD)
and the occurrence of thrombotic
events after PCI (3,4). The
vasodilator-stimulated phospho-
protein (VASP) index is the
most specific platelet assay to
assess PR inhibition related to
P2Y12–adenosine diphosphate
(ADP) receptor antagonists. A
recent consensus has been pub-
lished, on the basis of receiver-
operating characteristic (ROC)
curve analysis, regarding the pre-
dictive value of various platelets
assays to predict major adverse
cardiac events (MACE) after
PCI. In this consensus report,
HTPR was defined as a VASP
ndex 50% (3). This cutoff value exhibited very high
egative predictive value for thrombotic events in several
rials and has therefore been used to tailor therapy to
mprove clinical outcomes in patients undergoing PCI (5,6).
Prasugrel is a third-generation thienopyridine that has
emonstrated faster and more potent P2Y12-ADP receptor
inhibition than clopidogrel (7). Like clopidogrel, prasugrel is
a prodrug that requires bioactivation steps, including biotrans-
formation by hepatic cytochromes into actives metabolites. In
TRITON–TIMI 38 (Trial to Assess Improvement in Thera-
peutic Outcomes by Optimizing Platelet Inhibition With
Prasugrel–Thrombolysis In Myocardial Infarction 38), pra-
sugrel therapy resulted in a significant reduction in MACE
after PCI compared with clopidogrel in patients with ACS
(8). Its benefit, within the first 30 days, was related to a
reduction in recurrent thrombotic events, including early
stent thrombosis. This benefit is related to the favorable
pharmacodynamic profile of prasugrel compared with clopi-
dogrel, as these 2 drugs share similar active metabolites (9).
Interestingly, in a recently published substudy of TRI-
TON–TIMI 38, the investigators observed a relatively high
rate of HTPR, as defined using the consensus definition, in
patients receiving prasugrel therapy (10). However, to date,
a potential link between PR inhibition and recurrent throm-
botic events after PCI has not been evaluated in patients
receiving prasugrel therapy. In the present study, we aimed
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
CABG  coronary artery
bypass grafting
CV  cardiovascular
HTPR  high on-treatment
platelet reactivity
LD  loading dose
MACE  major adverse
cardiac event(s)
MFI  mean fluorescence
intensity
PCI  percutaneous
coronary intervention
PGE1  prostaglandin E1
PR  platelet reactivity
ROC  receiver-operating
characteristic
TIMI  Thrombolysis In
Myocardial Infarction
VASP  vasodilator-
stimulated phosphoproteinto investigate the relationship between PR inhibition andthe occurrence of MACE in patients undergoing successful
PCI for ACS and receiving prasugrel.
Methods
A prospective multicenter study was performed. Patients
presenting with ACS and undergoing successful PCI who
received prasugrel and gave informed consent to participate
in the study were eligible. Patients were enrolled in the
study between February and September 2010. The protocol
was approved by each of the local ethics committees and was
in accordance with the Declaration of Helsinki.
Exclusion criteria were failed PCI, cardiac arrest, contra-
indications to antiplatelet therapy, a platelet count 100
/l, history of bleeding diathesis, concurrent severe illness
ith expected survival 1 month, surgery within 1 month
or scheduled in the following year, age over 75 years,
warfarin or other oral anticoagulant therapy, weight 60
g, history of stroke, noncompliance with therapy, or an
nadequate prasugrel LD. Five patients were excluded from
he study because they did receive concomitant anticoagu-
ant therapy (warfarin) after PCI.
R measurements. Blood samples for VASP index analy-
is were drawn by atraumatic venipuncture of the antecubi-
al vein at least 6 h and within 12 h after prasugrel LD. The
nitial blood drawn was discarded to avoid measuring
latelet activation induced by needle puncture; blood was
ollected into a Vacutainer (Becton, Dickinson and Com-
any, Franklin Lakes, New Jersey) containing 3.8% triso-
ium citrate and filled to capacity. The Vacutainer was
nverted 3 to 5 times for gentle mixing and sent immediately
o the hemostasis laboratory. VASP index phosphorylation
nalysis was performed within 24 h of blood collection by an
xperienced investigator using Platelet VASP kits (Diag-
ostica Stago, Asnières, France) (4,5). Briefly, a citrated
lood sample was incubated with prostaglandin E1 (PGE1)
r with PGE1 and ADP 10 mol/l for 10 min and fixed
with paraformaldehyde, after which the platelets were per-
meabilized with a nonionic detergent. Analyses were per-
formed on an EPICS XL-MCL flow cytometer (Beckman
Coultronics, Margency, France), the platelet population was
identified from its forward and side scatter distribution, and
10,000 platelets were gated. VASP index was calculated
from the mean fluorescence intensity (MFI) of samples
incubated with PGE1 or PGE1 and ADP according to the
ormula: VASP [(MFIPGE1 MFIPGE1_ADP)/MFIPGE1]
100. HTPR was defined as a VASP index  50% according
to the consensus definition (3).
PCI. PCI was performed according to international guide-
lines, using a standard technique through the radial or
femoral route. Successful stent implantation was achieved in
all patients. Either a drug-eluting or a bare-metal stent was
used according to French Society of Cardiology guidelines.
The sheath was removed immediately at the end of the
procedure in all cases. Routine care before and after the
procedure was undertaken for all patients, including pre-
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July 26, 2011:467–73 Prasugrel and Thrombotic Events After PCItreatment with prasugrel (60-mg LD) at least 6 h before
VASP index measurement, followed by 10 mg/day for at
least 1 year. In addition, all patients received aspirin 75
mg/day for at least 1 year, with an LD of 250 to 500 mg
administered 12 h before stent implantation or at the time
of PCI in patients with ST-segment elevation myocardial
infarction. Compliance with aspirin and prasugrel was
assessed by nurses during hospital stay and by medical
contact at 1 month. Anticoagulation with unfractionated
heparin was begun in the intensive care unit before PCI.
During PCI, patients were anticoagulated with unfraction-
ated heparin (a bolus of 40 U/kg and additional heparin to
achieve an activated clotting time of 250 to 300 s). Antico-
agulation was stopped at the end of the procedure in all
patients. Glycoprotein IIb/IIIa inhibitors were administered
at the discretion of the interventional cardiologist and were
used according to guidelines. Failed PCI was defined as a
failure to obtain a residual stenosis 30% after stent
implantation and/or post-PCI TIMI flow grade 3.
Study endpoints. The primary endpoint was a composite
of cardiovascular (CV) death, nonfatal myocardial infarc-
tion, and stent thrombosis at 1 month. CV death was
considered as any death with a demonstrable CV cause or
any death that was not clearly attributable to a non-CV
cause. Stent thrombosis was defined according to the
Academic Research Consortium definition (11). Nonfatal
myocardial infarction was defined as recurrent ischemic
symptoms (20 min) and/or electrocardiographic changes
after PCI with an increase20% of troponin measured after
the recurrent event, with at least 1 value above the 99th
percentile of the reference range (12).
The secondary endpoint was the rate of major and minor
TIMI bleeding unrelated to coronary artery bypass grafting
(CABG) at 1 month.
Statistical analysis. All statistical analyses were performed
using SPSS version 17.0 (SPSS, Inc., Chicago, Illinois).
Continuous variables are expressed as mean  SD or as
median (range or interquartile range). Categorical variables
are expressed as frequencies and percents. Standard 2-sided
tests were used to compare continuous characteristics (Stu-
dent t or Mann-Whitney U tests) or categorical character-
istics (chi-square or Fisher exact tests) among patient
groups. Mann-Whitney U and Fisher exact tests were used
in the univariate analysis studying factors associated with
thrombotic events at 1 month. The sensitivity and specific-
ity of the VASP index to predict thrombotic events were
calculated at different thresholds in a ROC curve analysis.
The “optimal” cutoff value was defined by the highest
Youden index value (sensitivity  specificity  1). A
omplementary analysis compared the time to thrombotic
vents between HTPR and good responder groups using
he Kaplan-Meier method. Survival curves were com-
ared using the log-rank test. A p value 0.05 was
onsidered significant.esults
aseline demographic, clinical, angiographic, and biological
haracteristics are summarized in Table 1. A total of 301
atients were enrolled. The majority of the study population
ere men (n  267 [88.7%]), with a mean age of 58.1 
10.4 years. The prevalence of diabetes mellitus was 23.3%.
All patients had ACS at the time of inclusion; 42.5% of the
patients were included after ST-segment elevation myocar-
dial infarction.
The mean VASP index after a 60-mg LD of prasugrel
was 34.3  23.1% (range 5% to 76.6%). We observed large
interindividual variability in prasugrel responsiveness, with
VASP indexes ranging from 1% to 82.8% (Fig. 1). Al-
though the vast majority of patients (74.8%) were consid-
ered to have optimal PR inhibition, using a 50% cutoff value
to define HTPR, 76 patients (25.2%) were considered to
have insufficient PR inhibition after prasugrel LD. In
addition, 101 patients (33.6%) had VASP indexes 20%
after prasugrel LD.
The 30-day outcomes are displayed in Table 2. Three
patients were lost to follow-up. No patient underwent
CABG during the follow-up period. The primary endpoint
was met in 8 patients within the first month after PCI.
There was 1 CV death related to a definite stent thrombosis,
Baseline Demographic, Clinical, Angiographic,and B ological Ch racteristics (n  301)Table 1 Baseline Demographic, Clinic l, Angiographic,and Biological Characteristics (n  301)
Age (yrs) 58.1 10.4 (51–64)
Men 267 (88.7%)
BMI (kg/m2) 28.7 13.6 (24.2–30.9)
History of MI 57 (18.9%)
CV risk factors
Smoking 154 (51.2%)
Hypercholesterolemia 146 (48.5%)
Diabetes mellitus 70 (23.3%)
Hypertension 122 (40.5%)
Family history of CAD 64 (21.3%)
Clinical setting
STEMI 128 (42.5%)
NSTEMI 100 (33.2%)
UA 73 (24.3%)
Angiography and intervention
Number of treated vessels 1.2 0.4 (1–1.5)
Number of stents per patients 1.33 0.8 (1–2)
Number of DES per patient 0.7 0.9 (1–2)
GP IIb/IIIa inhibitor use 44 (14.6%)
Biology
Leukocytes (g/l) 10.4 3.5 (7.7–14.8)
Hemoglobin (g/dl) 13.9 1.5 (11.6–15.3)
Platelets (103/l) 228 68 (164–270)
Fibrinogen (g/l) 3.7 1.1 (3–4.2)
Values are mean  SD (range) or n (%).
BMI  body mass index; CAD  coronary artery disease; CV  cardiovascular; DES 
drug-eluting stent(s); GP  glycoprotein; MI  myocardial infarction; NSTEMI  non–ST-segment
elevation myocardial infarction; STEMI  ST-segment elevation myocardial infarction; UA 
unstable angina.
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Prasugrel and Thrombotic Events After PCI July 26, 2011:467–733 nonfatal definite stent thromboses, and 4 nonfatal myo-
cardial infarctions. The secondary endpoint was met in 5
patients, with 2 major and 3 minor non-CABG-related
TIMI bleeding events. Major bleeds were 1 puncture site
hematoma and 1 gastrointestinal bleed, both requiring
blood transfusion (Table 2).
Relationship between PR and CV events at 1 month.
The mean VASP index was significantly higher in patients
experiencing recurrent thrombotic events compared with
those free of events at 1 month (64.4  14.4% vs. 33.4 
2.7%, p  0.001; interquartile range: 55.5% to 76.2% and
4% to 47.6%, respectively). When comparing patients with
nd without MACE at 1 month, the 2 factors significantly
ssociated with thrombotic events were the VASP index
p  0.001) and hypercholesterolemia (p  0.032) (Table 3).
No difference could be observed between patients with a
minor or major non-CABG-related TIMI bleeding at 1
month and those without regarding the VASP index (30 
17.8% vs. 34.3  23.1%, p  0.70).
ROC analysis was performed to evaluate the predictive
value of the VASP index for thrombotic events. The area
under the curve was 0.86. The optimal cutoff value for the
VASP index to predict CV events was 53.5%, with sensi-
tivity of 87.5% and specificity of 76.5%. For this cutoff
value, the positive and negative predictive values were 10.4%
and 99.6%, respectively. The 50% cutoff value mentioned in
the consensus document had sensitivity of 87.5% and
specificity of 79.5%. The positive and negative predictive
values of this cutoff value were 9.2% and 99.6%, respectively
Figure 1 VASP Index After Prasugrel LD
Although the vast majority of patients had platelet reactivity (PR) below 50%,
25.2% were considered to have high on-treatment platelet reactivity (HTPR). LD
 loading dose; VASP  vasodilator-stimulated phosphoprotein.(Fig. 2).
r
VComparison between good responders and patients with
HTPR. We compared the good responder and HTPR
groups to evaluate the relationship between VASP index
and in-hospital thrombotic events or bleeding (Table 4).
There were no differences between these 2 groups regarding
demographic, clinical, angiographic, or biological data, ex-
cept for sex (p  0.007).
Kaplan-Meier analysis demonstrates that patients with
HTPR had significantly worse 1-month outcomes com-
pared with good responders (9.2% vs. 0.4%, log-rank p 
.001) (Fig. 3).
All but 1 patient with non-CABG-related TIMI major and
inor bleeding events had VASP indexes 50%. However,
here was no difference between the HTPR and good re-
ponder groups regarding TIMI bleeding events (p  1.00).
Discussion
The present study demonstrates that a significant number of
patients receiving prasugrel for ACS and treated by PCI have
insufficient PR inhibition as assessed by the VASP index. Of
importance, these patients with HTPR after prasugrel LD had
a significantly higher rate of recurrent thrombotic events
during the 1-month follow-up period after PCI.
Prasugrel is a new-generation thienopyridine with a faster
onset of action and a higher potency, which translate into
improved outcomes compared with clopidogrel in patients
with ACS treated with PCI (7,8). In the present study, we
observed that 25% of patients with ACS have HTPR after
a prasugrel LD, which is similar to that observed in a
substudy of TRITON–TIMI 38. This number is lower than
that observed after clopidogrel LD, which was about 50%
using the same platelet assay (5,6). Furthermore, in the
present study, we observed that patients with HTPR after
prasugrel LD experienced a higher rate of thrombotic events
than those with adequate response to the drug. In addition,
in the present study, ROC analysis observed a similar cutoff
value of the VASP index for thrombotic events (53.5%)
compared with the consensus definition. Consistent with
previous reports in the clopidogrel era, this cutoff value had
a very high negative predictive value for thrombotic events
with prasugrel therapy (3,13).This result is also consistent
1-Month Outcomes in GR (VASP Index <50%)and i Patients With HTPR (VASP Index >50%)Table 2 1-Mon Outcomes in GR (VASP Index <50%)and in Patients With HTPR (VASP Index >50%)
Outcome
GR
(n  225)
HTPR
(n  76) p Value
CV death 1 0
Recurrent ACS 0 4
Stent thrombosis 0 3
All MACE 1 7 0.001
Major TIMI bleeds 2 0
Minor TIMI bleeds 2 1
All TIMI bleeds 4 1 0.70
ACS  acute coronary syndromes; GR  good responders; HTPR  high on-treatment platelet
eactivity; MACE  major adverse cardiac event(s); TIMI  Thrombolysis In Myocardial Infarction;
ASP  vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1.
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July 26, 2011:467–73 Prasugrel and Thrombotic Events After PCIwith the fact that prasugrel and clopidogrel share similar
properties and in particular similar active metabolites. The
main difference between the 2 drugs is in fact related to the
efficiency of their biotransformation pathways (9).
Prasugrel therapy was associated in TRITON–TIMI 38
with a higher rate of bleeding events, which may be
related to its higher potency. Although a large number of
patients had very low PR after prasugrel LD in the
Univariate Analysis Comparing Patients With anTable 3 Univariate Analysis Comparing Pati
Value No
Age (yrs) 59.0 (50.5–66
Sex
Female 34 (11.6%)
Male 259 (88.4%)
BMI (kg/m2) 27.1 (24.3–30
History of MI
No 236 (80.5%)
Yes 57 (19.5%)
CV risk factors
Smoking
No 144 (49.1%)
Yes 149 (50.9%)
Hypercholesterolemia
No 154 (52.6%)
Yes 139 (47.4%)
Diabetes mellitus
No 225 (76.8%)
Yes 68 (23.2%)
Hypertension
No 173 (59.0%)
Yes 120 (41.0%)
Family history of CAD
No 232 (79.2%)
Yes 61 (20.8%)
Clinical presentation
STEMI 139 (47.4%)
NSTEMI 89 (30.4%)
UA 65 (22.2%)
Angiography and intervention
Number of treated vessels 1.0 (1.0–1.0
Number of stents 1.0 (1.0–2.0
Number of DES per patient 0.0 (0.0–1.0
GP IIb/IIIa inhibitors
No 251 (85.7%)
Yes 42 (14.3%)
Biology
Leukocytes (g/l) 9.8 (7.7–12.
Platelets (103/l) 223.0 (183.0–2
Hemoglobin (g/dl) 14.1 (13.1–15
Fibrinogen (g/l) 3.5 (3.0–4.2
VASP index (%) 29.3 (14.0–47
50 69 (23.5%)
50 224 (76.5%)
Values are median (interquartile range) or n (%).
Abbreviations as in Tables 1 and 2.present study, the rate of TIMI bleeding events was low, iand no relationship could be found between PR and
bleeding (14). However, despite the lack of association
between PR and bleeding events in the present study,
previous trials using clopidogrel have suggested that there
is an association between excessive PR inhibition and
bleeding complications. These findings suggest that there
may a therapeutic window of P2Y12-ADP receptor an-
agonists to reach to prevent thrombotic events and not
thout EventsWith and Without Events
Event
p ValueYes
56.5 (51.0–64.0) 0.80
0 (0%) 0.60
8 (100.0%)
25.8 (24.2–28.5) 0.40
8 (100.0%) 0.40
0 (0%)
3 (37.5%) 0.70
5 (62.5%)
1 (12.5%) 0.03
7 (87.5%)
6 (75.0%) 1.00
2 (25.0%)
6 (75.0%) 0.50
2 (25.0%)
5 (62.5%) 0.40
3 (37.5%)
5 (62.5%) 0.80
2 (25.0%)
1 (12.5%)
1.0 (1.0–1.5) 0.50
1.0 (1.0–2.0) 1.00
0.0 (0.0–0.5) 0.20
6 (75.0%) 0.30
2 (25.0%)
13.6 (8.5–14.8) 0.30
210.0 (164.0–236.0) 0.30
13.2 (11.6–15.3) 0.30
3.6 (3.4–3.9) 0.80
64.9 (55.5–76.2) 0.001
7 (87.5%) 0.001
1 (12.5%)d Wients
.0)
.9)
)
)
)
6)
70.0)
.1)
)
.6)ncrease the bleeding risk (3).
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Prasugrel and Thrombotic Events After PCI July 26, 2011:467–73Although in the present study, the VASP index was used
to monitor PR inhibition, other platelet assays, such as the
Multiplate analyzer (Verum Diagnostica GmbH, Munich,
Germany) and the VerifyNow P2Y12 (Accumetrics, Inc.,
San Diego, California), have been shown to be of similar
predictive value (3).
In the present study, no baseline demographic or clinical
characteristic was predictive of HTPR but sex. This result
illustrates the higher potency of the drug over clopidogrel,
for which body mass index, diabetes, clinical setting, and
age were independent predictors of HTPR together with
cytochrome 2C19 polymorphism (15). Consistent with a
potential impact of sex on PR, Hobson et al. (16) suggested
that women were more likely to have a higher clotting
tendency with lower response to both aspirin and clopi-
dogrel. Given the small number of women included in the
present study, this result requires confirmation in future
trials.
Given the results of the present study, although signifi-
cantly reducing thrombotic events after PCI because of its
superior potency, prasugrel therapy may require PR moni-
toring to enable optimal PR inhibition to be achieved,
which may lead to improved outcomes in all patients. We
have previously demonstrated that adjusting the LD of
clopidogrel to achieve a VASP index50% in patients with
HTPR improved clinical outcomes by reducing the rate of
early stent thrombosis (5,6). The GRAVITAS (Gauging
Figure 2 ROC Analysis of the Predictive Value of the
VASP Index for Thrombotic Events After PCI
The vasodilator-stimulated phosphoprotein (VASP) index has high sensitivity
and specificity for thrombotic events after percutaneous coronary intervention
(PCI) in the prasugrel era (area under the receiver-operating characteristic
[ROC] curve  0.86). Solid line  AUC; dashed line  ROC analysis.Responsiveness With a VerifyNow Assay: Impact onThrombosis and Safety) study aimed to confirm these
preliminary findings by showing that increased clopidogrel
doses in patients with HTPR could be of clinical benefit.
The results of this trial were negative. However, the dose
adjustment strategy was notably insufficient, and because the
majority of patients were at low risk for thrombotic events,
the study was underpowered to test the hypothesis (17).
Thus, the concept of an optimal level of PR inhibition to
further improve clinical outcomes remains to be confirmed.
Such individualized therapy could be of critical interest if
additional studies support an association between bleeding
events and PR inhibition in the prasugrel era. In fact, the
therapeutic window could therefore be used to balance
between the thrombotic and bleeding risk.
Study limitations. Limitations of the present study in-
cluded the relatively small sample size and rate of thrombotic
events. In fact, because the number of event is small, this
finding should be considered as hypothesis generating and
warrants a larger trial to confirm the relationship between PR
inhibition under prasugrel therapy and thrombotic events.
However, the results are supported by the large amount of
published data supporting this link in the clopidogrel era.
Conclusions
Despite the use of a prasugrel LD, a significant number of
patients with ACS undergoing PCI do not achieve optimal
Comparison of Baseline CharacteristicsBetween GR and Patients With HTPRTable 4 Comparison of Baseline CharacteristicsBetween GR and Patients With HTPR
Variable
GR
(n  225)
HTPR
(n  76) p Value
Age (yrs) 58.4 10 57.4 12 0.30
Men 206 (92%) 63 (81.6%) 0.07
BMI (kg/m2) 28.8 15.4 28.4 5 0.40
History of MI 40 (17.7%) 17 (22.4%) 0.40
CV risk factors
Smoking 114 (50.6%) 40 (52.6%) 0.80
Hypercholesterolemia 110 (48.9%) 36 (47.4%) 0.50
Diabetes mellitus 54 (24%) 16 (21%) 0.60
Hypertension 92 (40.9%) 30 (39.5%) 0.80
Family history of CAD 45 (20%) 19 (25%) 0.40
Clinical setting
STEMI 97 (43.1%) 31 (40.8%)
NSTEMI 76 (33.8%) 24 (31.6%) 0.90
UA 52 (23.1%) 21 (27.6%)
Angiography and intervention
Number of treated vessels 1.2 0.4 1.1 0.3 0.50
Number of stents per patient 1.4 0.8 1.2 0.9 0.10
Number of DES per patient 0.7 0.9 0.7 0.8 0.60
GP IIb/IIIa inhibitor use 35 (15.6%) 9 (11.8%) 0.50
Biology
Leukocytes (g/l) 10.4 3.3 10.3 3.6 0.90
Hemoglobin (g/dl) 14 1.6 13.7 1.5 0.11
Platelets (103/l) 229 63 226 84 0.80
Fibrinogen (g/l) 3.5 0.9 3.8 1.1 0.20Values are mean  SD or n (%).
Abbreviations as in Tables 1 and 2.
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July 26, 2011:467–73 Prasugrel and Thrombotic Events After PCIPR inhibition. Such patients have a higher risk for MACE
after PCI. This result suggests that PR monitoring to tailor
P2Y12-ADP receptor antagonist therapy may be of interest
with prasugrel use to further improve patient outcomes.
Larger trials are needed to confirm these hypotheses.
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